FDA-approved1,2Evidence: Smaller human trialsHormones · Sexual and reproductive health

Cetrorelix1

Also called Cetrotide1,2

Key takeaway

Cetrorelix is a synthetic decapeptide that blocks the gonadotropin-releasing hormone (GnRH) receptor, and the active ingredient in Cetrotide.1,2 FDA approved Cetrotide in 2000 to prevent a premature surge of luteinizing hormone (LH) in women undergoing controlled ovarian stimulation for fertility treatment such as IVF.1,2 Its label describes five clinical trials in which 732 women received it, including two well-controlled studies with active comparators.1

Cetrorelix at a glance

What it isA synthetic analogue of GnRH with amino acids changed at five positions, which blocks rather than activates the GnRH receptor, according to the label.1
FDA statusFDA-approved. Drugs@FDA lists Cetrotide with an original approval date of August 11, 2000. The cited label has no boxed warning.1,2
Human evidenceTwo Phase 2 and three Phase 3 trials in women undergoing ovarian stimulation, including two well-controlled studies with active comparators, described in the label.1
Evidence strengthSmaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned

What is cetrorelix?

Cetrorelix is a synthetic decapeptide analogue of gonadotropin-releasing hormone (GnRH) with amino-acid substitutions at positions 1, 2, 3, 6 and 10 that give it GnRH-blocking activity, according to the label.1

In the United States it is the active ingredient of Cetrotide, from EMD Serono, according to Drugs@FDA.2

How does cetrorelix work?

The label explains that a midcycle surge of LH triggers ovulation. Cetrorelix competes with natural GnRH for its pituitary receptor and so controls the release of LH and FSH.1

The label states that it delays the LH surge, and therefore ovulation, and that its effects reverse after treatment stops. No initial release of the body’s own gonadotropins has been detected, consistent with a blocker.1

What do human studies show?

The label reports that 732 women aged 19 to 40 were treated with Cetrotide in five trials, two Phase 2 studies and three Phase 3 studies, which excluded women with polycystic ovary syndrome, low ovarian reserve or advanced endometriosis.1

Effectiveness was established separately for two treatment approaches in two well-controlled studies using active comparators, with a third Phase 3 study that had no comparison group, according to the label.1

What the evidence base contains

  • Controlled human trial Two adequate and well-controlled Phase 3 studies with active comparators in women undergoing controlled ovarian stimulation, described in the label.1
  • Small, short, or incompletely reported human study A third, non-comparative Phase 3 study in 303 women, described in the label.1

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is cetrorelix FDA-approved?

Yes. Drugs@FDA lists Cetrotide, application NDA 021197, with an original approval date of August 11, 2000.2

The Cetrotide label cited here (DailyMed SPL version 18, published September 29, 2025) states that it is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.1

The label has no boxed warning. It states that it should be prescribed by physicians experienced in fertility treatment and that pregnancy must be excluded before starting.1

Timeline

  1. FDA approves Cetrotide, according to Drugs@FDA.2
  2. DailyMed publishes the Cetrotide label version cited on this page.1

What is still unknown?

Its effects in women excluded from the trials, including those with polycystic ovary syndrome, low ovarian reserve or advanced endometriosis, according to the label.1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Cetrorelix: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Cetrorelix are a bounded selection, not every registration or paper about Cetrorelix. For the years before Cetrorelix was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Cetrorelix as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Cetrorelix in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Cetrotide for use in controlled ovarian stimulation. The label describes five trials in which 732 women received cetrorelix, including two well-controlled studies with active comparators.↗↗

Status sources checked through November 15, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Cetrorelix?

FDA-approved as Cetrotide for use in controlled ovarian stimulation. The label describes five trials in which 732 women received cetrorelix, including two well-controlled studies with active comparators.↗↗

The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
18
Drugs@FDA applications
7

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Collection changes

What did PeptideScanner add most recently?

  1. Clinical trials · added November 15, 2026

    ClinicalTrials.gov record NCT05326087↗Source date November 9, 2026
  2. Literature metadata · added November 15, 2026

    Comparison of Chitosan-Poloxamer Nanoparticles and Poloxamer-based In-Situ Forming Gel for Nose-to-Brain Delivery of Cetrorelix: In Vitro and Pharmacokinetic Studies in Rats.↗Source date September 24, 2026
  3. Regulatory · added November 15, 2026

    Drugs@FDA application ANDA218740↗Source date April 29, 2026

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Cetrorelix?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

56Selected dated records
58Connected citations
18Populated source years2000–2026
3/4Record lanes present

Registered human studies

Trial composition

25 of 26 selected trial records include at least one phase value; 26 of 26 include a status value in the retained structured contract.

PhasesNot applicable 7Phase 2 6Phase 3 6Phase 4 5Early Phase 1 2Phase 1 1
Status at observationCompleted 24Active, not recruiting 1Not yet recruiting 1

A phase value is unavailable here for 1 selected record; this is not counted as “no phase.”

PubMed bibliography

Publication composition

22 of 22 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 22Clinical Trial 6Research Support, Non-U.S. Gov't 4Comparative Study 3Clinical Trial, Phase II 2English Abstract 2Randomized Controlled Trial 2Review 2Case Reports 1Multicenter Study 1Research Support, N.I.H., Extramural 1Research Support, U.S. Gov't, P.H.S. 1Validation Study 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
7
FDA Federal Register documents
1
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
56

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 56 dated records

Research hub

Explore the Cetrorelix evidence record

Open all 56 records →
56Dated records
3Evidence types
56Cited public sources
18Source years

Change ledger

Recently changed for Cetrorelix

Open all 56 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT00244452

PeptideScanner retained ClinicalTrials.gov record NCT00244452 at 2026-11-15T22:02:39.332Z. Its registry update date was 2008-03-31, and PeptideScanner's reviewed identity mapping was cetrorelix.

PeptideScanner change date
November 15, 2026
Cited source date
March 31, 2008
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00439829

PeptideScanner retained ClinicalTrials.gov record NCT00439829 at 2026-11-15T22:02:39.332Z. Its registry update date was 2010-05-25, and PeptideScanner's reviewed identity mapping was cetrorelix.

PeptideScanner change date
November 15, 2026
Cited source date
May 25, 2010
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00628121

PeptideScanner retained ClinicalTrials.gov record NCT00628121 at 2026-11-15T22:02:39.332Z. Its registry update date was 2008-03-04, and PeptideScanner's reviewed identity mapping was cetrorelix.

PeptideScanner change date
November 15, 2026
Cited source date
March 4, 2008
Evidence lane
Clinical trials

Official-source collections

Source records for Cetrorelix

Open the full research atlas →
PubMed22

22 with attributed title, venue, publication-date, and type metadata.

  1. Comparison of Chitosan-Poloxamer Nanoparticles and Poloxamer-based In-Situ Forming Gel for Nose-to-Brain Delivery of Cetrorelix: In Vitro and Pharmacokinetic Studies in Rats.AAPS PharmSciTech · 2026 06 04
  2. Synthesis of Diastereomerically Pure Cetrorelix Acetate by Using Fmoc Solid-Phase Peptide Synthesis (SPPS) Strategy: A Commercially Viable Approach.Journal of peptide science : an official publication of the European Peptide Society · 2025 Jun
  3. Extrahepatic in vitro metabolism of peptides; comparison of human kidney and intestinal S9 fraction, human plasma and proximal tubule cells, using cyclosporine A, leuprorelin, and cetrorelix as model…Journal of pharmaceutical and biomedical analysis · 2022 12 31
Explore all selected literature →
ClinicalTrials.gov26

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT05326087Registry update November 9, 2026 · current at observation
  2. NCT05951400Registry update April 15, 2026 · completed at observation
  3. NCT02892942Registry update April 3, 2026 · completed at observation
Explore all selected trial records →Explore all public record history →
Drugs@FDA7

Original-submission application metadata connected by exact reviewed active-ingredient names.

  1. ANDA218740Full FDA chronology · original submission status AP 2026-04-29
  2. ANDA218061Full FDA chronology · original submission status AP 2025-06-03
  3. ANDA218150Full FDA chronology · original submission status AP 2024-04-25
  4. ANDA214540Full FDA chronology · original submission status AP 2024-04-24
  5. ANDA217776Full FDA chronology · original submission status AP 2024-04-16
Explore all selected FDA applications →Explore 0 dated submissions and 0 documents for Cetrorelix →

Evidence types

Coverage by source year

Selected records span August 11, 2000 to November 9, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. National Library of Medicine1
  • U.S. Food and Drug Administration2
Dated updates connected to this profile · 56

Updates connected to this profile

Open the full cross-source timeline →
  1. Clinical trials

    ClinicalTrials.gov record NCT05326087↗

    PeptideScanner retained ClinicalTrials.gov record NCT05326087 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was cetrorelix.↗

  2. Literature metadata

    Comparison of Chitosan-Poloxamer Nanoparticles and Poloxamer-based In-Situ Forming Gel for Nose-to-Brain Delivery of Cetrorelix: In Vitro and Pharmacokinetic Studies in Rats.↗

    PubMed lists PMID 42243608 in AAPS PharmSciTech as Journal Article, Comparative Study, with publication-date metadata of 2026-06-04 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Regulatory

    Drugs@FDA application ANDA218740↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 218740 with status AP dated 2026-04-29, and names cetrorelix acetate among the application record's active ingredients.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT05951400↗

    PeptideScanner retained ClinicalTrials.gov record NCT05951400 at 2026-11-15T22:02:39.332Z. Its registry update date was 2026-04-15, and PeptideScanner's reviewed identity mapping was cetrorelix.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT02892942↗

    PeptideScanner retained ClinicalTrials.gov record NCT02892942 at 2026-11-15T22:02:39.332Z. Its registry update date was 2026-04-03, and PeptideScanner's reviewed identity mapping was cetrorelix.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT06378268↗

    PeptideScanner retained ClinicalTrials.gov record NCT06378268 at 2026-11-15T22:02:39.332Z. Its registry update date was 2026-03-20, and PeptideScanner's reviewed identity mapping was cetrorelix.↗

  7. Literature metadata

    Extrahepatic in vitro metabolism of peptides; comparison of human kidney and intestinal S9 fraction, human plasma and proximal tubule cells, using cyclosporine A, leuprorelin, and cetrorelix as model…↗

    PubMed lists PMID 36630767 in Journal of pharmaceutical and biomedical analysis as Journal Article, with publication-date metadata of 2022-12-31 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    Synthesis of Diastereomerically Pure Cetrorelix Acetate by Using Fmoc Solid-Phase Peptide Synthesis (SPPS) Strategy: A Commercially Viable Approach.↗

    PubMed lists PMID 40386934 in Journal of peptide science : an official publication of the European Peptide Society as Journal Article, with publication-date metadata of 2025-06 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Regulatory

    Drugs@FDA application ANDA218061↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 218061 with status AP dated 2025-06-03, and names cetrorelix acetate among the application record's active ingredients.↗

  10. Clinical trials

    ClinicalTrials.gov record NCT04414748↗

    PeptideScanner retained ClinicalTrials.gov record NCT04414748 at 2026-11-15T22:02:39.332Z. Its registry update date was 2025-05-31, and PeptideScanner's reviewed identity mapping was cetrorelix.↗

  11. Clinical trials

    ClinicalTrials.gov record NCT06608186↗

    PeptideScanner retained ClinicalTrials.gov record NCT06608186 at 2026-11-15T22:02:39.332Z. Its registry update date was 2025-01-22, and PeptideScanner's reviewed identity mapping was cetrorelix.↗

  12. Clinical trials

    ClinicalTrials.gov record NCT05767086↗

    PeptideScanner retained ClinicalTrials.gov record NCT05767086 at 2026-11-15T22:02:39.332Z. Its registry update date was 2024-10-15, and PeptideScanner's reviewed identity mapping was cetrorelix.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    CETROTIDE (cetrorelix acetate) kit · SPL version 18 · published 2025-09-29 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA: CETROTIDE (cetrorelix acetate), NDA 021197 · original approval August 11, 2000 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026